Job Description
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at jnj.com. As guided by Our Credo, Johnson & Johnson is responsible to our employees who work with us throughout the world. We provide an inclusive work environment where each person is considered as an individual. At Johnson & Johnson, we respect the diversity and dignity of our employees and recognize their merit. Job Function Discovery & Pre-Clinical/Clinical Development Job Sub Function Clinical Development & Research – MD Job Category People Leader All Job Posting Locations: Cambridge, Massachusetts, United States of America, Raritan, New Jersey, United States of America, San Diego, California, United States of America, Spring House, Pennsylvania, United States of America, Titusville, New Jersey, United States of America Job Description Johnson & Johnson, is recruiting for a Vice President, Head of Neuropsychiatry Clinical Development to be based at one of our sites in Titusville, NJ; Raritan, NJ; Cambridge, MA; Spring House, PA; La Jolla, CA. Our expertise in Innovative Medicine is informed and inspired by patients, whose insights fuel our science-based advancements. Visionaries like you work on teams that save lives by developing the medicines of tomorrow. Our Neuroscience team tackles the world’s toughest brain health challenges including multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, myasthenia gravis, epilepsy, major depressive disorder, bipolar disorder, schizophrenia, and autism. This patient-focused team helps address some of the most complex diseases of our time. Join us in developing treatments, finding cures, and pioneering the path from lab to life while championing patients every step of the way. Learn more at https://www.jnj.com/innovative-medicine The VP, Head of Neuropsychiatry (NP) Clinical Development is accountable for strategic leadership and oversight of all Neuropsychiatry related clinical programs and clinical development activities from Phase 2b through the end of Phase 3, certain phase 4 studies may also be in scope. Responsibilities Core member of the Disease Area Leadership Team (DALT) and the Neuroscience Development Leadership Team The VP NP has responsibility for the NP development strategy in alignment with Disease Area Strategies, and for assuring an integrated, efficient, effective and timely implementation of that strategy. The VP NP ensures that CDTs develop thoughtful, integrated asset development strategies and appropriately capture these in the Asset Development Plan document. Helping teams identify and addresses the key issues, alternative strategies considered, and key stages of development (with associated GO/NO GO decision points and criteria). The VP NP working with the Compound Development Team Leader (CDTL) assures that the issues and concerns of the functional partners are addressed so that the clinical strategy and the implementation of that strategy is comprehensive, effective, and highly integrated. The VP NP has ultimate responsibility and accountability within NP for protocol design and for final protocols, clinical study reports, and clinical components of regulatory packages/submissions. He or she may delegate some of these responsibilities, as appropriate. The VP NP represents the clinical development group to the rest of the franchise, and to the units of JRD and other Janssen R&D companies. The VP NP is responsible for decisions regarding external presentation of clinical research data, including timing and appropriateness of content. In this role, the VP NP will work with the CDTL, DAS lead and with functional partners from global medical affairs, health care compliance, legal regulatory, and other relevant groups. The VP NP is responsible for final approval of each compound’s risk language working closely with the Clinical Leader, the CDTL, and the Global Medical Safety (GMS) group representative The VP NP is responsible for assuring appropriate clinical input and direction for programs, and is expected to provide review and input, from the clinical development perspective, for all programs going f